Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
Kymera Therapeutics reported Q3 2026 results highlighted by positive Phase 1 healthy volunteer data for KT-579 (IRF5 degrader), which showed ≥90% median IRF5 degradation, robust suppression of inflammatory cytokines (88% TNFα, 94% IL-1β, 98% IFNβ inhibition) and a safety profile comparable to placebo. The company completed dosing in the KT-621 (STAT6) BROADEN2 Phase 2b atopic dermatitis trial, with topline data due by year-end 2026, and plans to start the KT-579 LUMORA Phase 1b lupus trial by early 2027. Financially, Kymera posted a $132.0 million net loss (EPS of -$1.32) with no collaboration revenue, versus $82.2 million net loss in Q3 2025, driven by a jump in R&D spend to $128.5 million.
Key figures
- Revenue
- 0
- Guidance
- no additional collaboration revenue expected in 2026; KT-621 topline data by year-end 2026; first AD Phase 3 trial by mid-2027; BREADTH asthma topline late 2027; KT-579 LUMORA lupus trial start by early 2027
- Revenue Yoy
- collaboration revenue $0 vs $2.8 million in Q3 2025
- Net loss
- 132000000
- Ga expense
- 18700000
- Rd expense
- 128500000
- Cash runway
- into 2029
- Irf5 degradation
- ≥90% median degradation across multiple MAD dose levels
- Cytokine inhibition
- 88% TNFα, 87% IL-12/23p40, 94% IL-1β, 98% IFNβ at Day 14
- Cash and investments
- 1645883000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.